Vandana Pokhriyal*, Preeti Kothiyal, Neeraj Kumar, Sudhakar Kaushik
Division of Pharmaceutical Sciences, Shri Guru Ram Rai Institute of Technology and Science, Dehradun, Uttarakhand, India
*Address for Corresponding Author
Vandana Pokhriyal
Division of Pharmaceutical Sciences, Shri Guru Ram Rai Institute of Technology and Science, Patel Nagar, Dehradun 248001, India
Abstract
Diabetes Mellitus is the commonly prevalent and diverse metabolic disorder caused by occurrence of hyperglycemia with disturbance of carbohydrate metabolism, fat & protein metabolism. Diabetic Neuropathy is the most common and debilitating complication of diabetes mellitus and results in pain and decreased motility. Long term hyperglycaemia elicits enhanced Polyol pathway, increased non-enzymatic glycation of various structural proteins, which moreover increased oxidative stress as well as altered the protein kinase C (PKC) activity and poly ADP-ribose polymerase (PARP) activation that are all inter-related for the cause and development of neuropathy. Microvascular complication Diabetic neuropathy leads various complications such as loss of sensation, foot ulcer, urinary tract infection, gangrene, sexual dysfunction. Treatment of Neuropathy consist two beneficial approaches: pathogenic treatment and symptomatic treatment. Diabetic neuropathy symptomatic treatment involves the use of tricyclic antidepressant, serotonin norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, Opioids and topical medication while pathogenic treatment include glycemic control, pancreas transplant, Alpha lipoic acid(antioxidant). Main goal of the treatment is to prevent neuropathic pain and complication associated with neuropathy.
Keywords: Diabetes, neuropathy, hyperglycemia, foot ulcer
